Patient characteristics and docetaxel exposure (n = 180)
| . | No. (%) . | Median . | 5–95% percentile . |
|---|---|---|---|
| Age (years) | 61 | 43–72 | |
| Sex | |||
| Male | 118 (66) | ||
| Female | 62 (34) | ||
| WHO performance status | |||
| 0 | 35 (19) | ||
| 1 | 113 (63) | ||
| 2 | 32 (18) | ||
| AAG (grams/liter) | 1.42 | 0.84–2.71 | |
| Time from diagnosis (month) | 4.7 | 0.6–39 | |
| >12 months | 48 (27) | ||
| Extent of disease | |||
| Number of disease sites | |||
| 1 | 48 (27) | ||
| 2 | 70 (39) | ||
| 3 | 42 (23) | ||
| ≥4 | 20 (11) | ||
| Liver metastasis | 34 (19) | ||
| Prior treatments | |||
| Chemotherapy | 52 (29) | ||
| Number of prior regimen | |||
| 0 | 128 (71) | ||
| 1 | 34 (19) | ||
| ≥2 | 18 (10) | ||
| Previous platinum | 43 (24) | ||
| Radiotherapy | 70 (39) | ||
| Docetaxel exposure | |||
| CL (liters/h) | 35.7 | 17.8–58.8 | |
| AUC (μg·h/ml) | 4.98 | 3.24–9.76 |
| . | No. (%) . | Median . | 5–95% percentile . |
|---|---|---|---|
| Age (years) | 61 | 43–72 | |
| Sex | |||
| Male | 118 (66) | ||
| Female | 62 (34) | ||
| WHO performance status | |||
| 0 | 35 (19) | ||
| 1 | 113 (63) | ||
| 2 | 32 (18) | ||
| AAG (grams/liter) | 1.42 | 0.84–2.71 | |
| Time from diagnosis (month) | 4.7 | 0.6–39 | |
| >12 months | 48 (27) | ||
| Extent of disease | |||
| Number of disease sites | |||
| 1 | 48 (27) | ||
| 2 | 70 (39) | ||
| 3 | 42 (23) | ||
| ≥4 | 20 (11) | ||
| Liver metastasis | 34 (19) | ||
| Prior treatments | |||
| Chemotherapy | 52 (29) | ||
| Number of prior regimen | |||
| 0 | 128 (71) | ||
| 1 | 34 (19) | ||
| ≥2 | 18 (10) | ||
| Previous platinum | 43 (24) | ||
| Radiotherapy | 70 (39) | ||
| Docetaxel exposure | |||
| CL (liters/h) | 35.7 | 17.8–58.8 | |
| AUC (μg·h/ml) | 4.98 | 3.24–9.76 |